News Jazz builds in epilepsy with $1.3bn Actio acquisition Jazz Pharma has dipped its toe into the M&A water again, agreeing to buy rare epilepsy drug developer Actio Bio for $820m upfront.
News Double IPOs headline this week's biotech financings This week saw two $250 million-plus initial public offering (IPO) filings for Neumora Therapeutics and RayzeBio, plus a record third-round financing for Generate Biomedici
News AZ seeking $1.5bn in annual savings by end-2029 AstraZeneca has launched a cost-cutting programme that will aim to slash $1.5bn a year off its costs, with the savings reinvested in R&D.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
